Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. REVERPLEG (argipressine (acétate d'))
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

REVERPLEG (argipressine (acétate d'))

Medicine - Posted on Oct 10 2024
Active substance (DCI)
  • argipressine (arginine vasopressine)
history (2)
  • 9/25/24

    REVERPLEG (argipressin) - Catecholamine-refractory hypotension following septic shock

    Summary of opinion Favourable opinion for the reimbursement of REVERPLEG (argipressin) in the treatment of catecholamine-ref...
    CAV :
    54321
    icône flèche
  • 2/27/19

    REVERPLEG (argipressine (acétate d'))

    Intérêt clinique insuffisant pour justifier son remboursement dans le traitement de l’hypotension réfractaire aux catécholam...
    icône flèche
Technical information
ATC code
  • H01BA01
Manufacturer
AOP ORPHAN PHARMACEUTICALS FRANCE
Presentation

REVERPLEG 40 U.I./2 mL, solution à diluer pour perfusion
5 ampoules en verre de 2 ml (CIP : 34009 550 556 3 1)
10 ampoules en verre de 2 ml (CIP : 34009 550 556 4 8)

All our publications
    Drug therapy Peripheral vascular diseases Vascular diseases - miscellaneous

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
REjHNWfS4MEqySSq